Sign In
Buy FATE
$0.97
+0.0090 (+0.93%)
At Close: Nov 17, 2025
Robert Bruce's Strategic Moves: AT&T Inc. Sees a -1.41% Portfolio Impact
04:02pm, Thursday, 13'th Nov 2025
Insightful Analysis of Robert Bruce (Trades, Portfolio)'s Third Quarter 2025 13F Filing Robert Bruce (Trades, Portfolio) recently submitted the 13F filing for
Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates
10:41am, Thursday, 13'th Nov 2025
Fate Therapeutics (FATE) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.4 per share a year ago.
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
08:30am, Thursday, 13'th Nov 2025
Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 04'th Nov 2025
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
11:01am, Tuesday, 04'th Nov 2025
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Cancer-Focused Stocks Showing Strong Pipeline Progress
12:35pm, Tuesday, 28'th Oct 2025
Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.
As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of “Hold” by Analysts
01:56am, Friday, 24'th Oct 2025
Shares of Fate Therapeutics, Inc. (NASDAQ: FATE - Get Free Report) have earned a consensus rating of "Hold" from the eight research firms that are covering the company, Marketbeat reports. One researc
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Thursday, 02'nd Oct 2025
SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Wednesday, 03'rd Sep 2025
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent
Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates
06:16pm, Tuesday, 12'th Aug 2025
Fate Therapeutics (FATE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.33 per share a year ago.
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
04:01pm, Tuesday, 12'th Aug 2025
First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus nephritis demonstrated durability of response with drug-free defini
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 05'th Aug 2025
SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
01:05pm, Thursday, 03'rd Jul 2025
SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s
Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report?
12:30pm, Thursday, 12'th Jun 2025
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
